ImmuneOnco Biopharmaceuticals Transfers Equity to Two Senior Management Members

MT Newswires Live09-16

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to transfer 7.0% equity interest in ImmuneCare Biopharmaceutical (Shanghai) to Jiaxing Changxin for 140,000 yuan, a Friday filing with the Hong Kong Exchange said.

The equity interest was given to Tian Wenzhi, the chairman of the board and a controlling shareholder of the company, and Zheng Qian, a member of the senior management of the target company, in recognition of the contributions of the two. Jiaxing Changxin holds the equity interest on behalf of the two.

Upon the completion of the transaction, the company will hold 93% equity interest in ImmuneCare Biopharmaceutical.

The company's shares closed over 35% higher on Monday.

Price (HKD): $6.68, Change: $+1.7, Percent Change: +35.22%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467481095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467481095","market":"us","top_or_hot":-1,"title":"ImmuneOnco Biopharmaceuticals Transfers Equity to Two Senior Management Members","media":"MT Newswires Live","content":"<html><body><p> ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to transfer 7.0% equity interest in ImmuneCare Biopharmaceutical (Shanghai) to Jiaxing Changxin for 140,000 yuan, a Friday filing with the Hong Kong Exchange said.</p><p>The equity interest was given to Tian Wenzhi, the chairman of the board and a controlling shareholder of the company, and Zheng Qian, a member of the senior management of the target company, in recognition of the contributions of the two. Jiaxing Changxin holds the equity interest on behalf of the two.</p><p>Upon the completion of the transaction, the company will hold 93% equity interest in ImmuneCare Biopharmaceutical.</p><p>The company's shares closed over 35% higher on Monday.</p><p>Price (HKD): $6.68, Change: $+1.7, Percent Change: +35.22%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Biopharmaceuticals Transfers Equity to Two Senior Management Members</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Biopharmaceuticals Transfers Equity to Two Senior Management Members\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 21:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to transfer 7.0% equity interest in ImmuneCare Biopharmaceutical (Shanghai) to Jiaxing Changxin for 140,000 yuan, a Friday filing with the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EQR","symbol_name":"资产住宅公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467481095","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467481095","pubTimestamp":1726491745,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to transfer 7.0% equity interest in ImmuneCare Biopharmaceutical (Shanghai) to Jiaxing Changxin for 140,000 yuan, a Friday filing with the Ho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EQR":"资产住宅公司","BK4585":"ETF&股票定投概念","BK1161":"生物科技","01541":"宜明昂科-B","BK4588":"碎股","BK4526":"热门中概股","BK4023":"应用软件","HKD":"尚乘数科","BK4215":"住宅房地产投资信托"},"translate_title":"ImmuneOnco Biopharmaceuticals向两名高级管理人员转让股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1,"HKD":1,"01541":0.9},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to transfer 7.0% equity interest in ImmuneCare Biopharmaceutical (Shanghai) to Jiaxing Changxin for 140,000 yuan, a Friday filing with the Hong Kong Exchange said.The equity interest was given to Tian Wenzhi, the chairman of the board and a controlling shareholder of the company, and Zheng Qian, a member of the senior management of the target company, in recognition of the contributions of the two. Jiaxing Changxin holds the equity interest on behalf of the two.Upon the completion of the transaction, the company will hold 93% equity interest in ImmuneCare Biopharmaceutical.The company's shares closed over 35% higher on Monday.Price (HKD): $6.68, Change: $+1.7, Percent Change: +35.22%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467481095"}